Yellow Tomorrow

Orano Med hope in the fight against cancer

Orano Med

hope in the fight against cancer

Orano Med, Orano’s medical subsidiary, is combining biotechnology and nuclear energy to develop targeted cancer treatments using the unique properties of lead-212 (212Pb).

Its work is fueling the hope that the international medical community will move toward less toxic, more effective treatments for patients with limited treatment options.

  • 62employees
  • 12developments in progress
  • 2units working on the production of lead-212 in France and the United States
  • 2laboratory projects for the production and distribution of radiopharmaceuticals in the United States and France (ATLabs)

The properties of lead-212

Lead-212 is a very rare radioactive isotope that comes from thorium. Orano’s expertise in cutting-edge nuclear technologies has made it possible to develop a unique process that contributes to the extraction and purification of lead-212. This rare metal is used in the development of several promising targeted cancer treatments referred to as “Targeted Alpha Therapy”.